TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of reocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lash ptosis grade improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lash ptosis symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheterization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: IPSS improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean reduction rates for inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean motor function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of remaining in SR at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery time from grade 3 to 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recovery time from grade 3 to 4 thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fitness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting SNS activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from cardiopulmonary causes
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in viable prostate tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular events (CVE)
Endpoint domain: Mortality/survival
Primary endpoint: pre-dialytic dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: intradialytic cramps
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of new ischemic brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of new ischemic brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Size of new ischemic brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sexual arousal sd score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body shape sd score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apoptosis index of lung cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of bcl-2 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage fractional shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative success rates of direct pulp capping materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life years (QALY) gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall failure rate of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventing recurrences of LBP
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: 10-year CVD event risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective vitrectomy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intraoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Timed Up & Go test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: organized physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: playing outside
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of target actions met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per additional action met
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: risk of a first CID event
Endpoint domain: Mortality/survival
Primary endpoint: risk of a sustained CID event
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in positive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tissue eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum half-lives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss maintenance (≥5% of initial weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent bladder control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of CD(3)(+), CD(4)(+), CD(4)(+)/CD(8)(+), CD(16)(+), CD(69)(+), CD(3)(+)/HLA-DR(+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of Life (QOL) advantages
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prepulse inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduced SABA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved treatment stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor and cognitive outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF levels of homovanillic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Recurrent Atrial Fibrillation (AF)
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetics profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebrovascular morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vision gain (≥15 letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected VA ≥20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VA ≤20/200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of clinical insomnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low birth weight prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in morbidity on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death from any cause assessed on day 28
Endpoint domain: Mortality/survival
Primary endpoint: Difference in the Yale Brown obsessive compulsive disorder checklist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-compliance
Endpoint domain: Adverse events/effects
Primary endpoint: VAS values after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triacylglycerol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: milk yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFCR at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ER prevalence at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADA trough level at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs and symptoms of stress and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cmax and AUClast of fimasartan and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical and mental health status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: GERD-health related quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Moderate or severe regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discontinuation of PPIs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TNF-alpha, interleukin-6 and high sensitive-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary excretion of 8-iso-PGF2alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean union time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Orthopedic Foot and Ankle Society ankle scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Shuffle cut performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA1c change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin dose stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lymphedema incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Length of inpatient hospitalization
Endpoint domain: Resource use
Primary endpoint: attentional test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: everyday attentional behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTS angle difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lachman test effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pivot shift test positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% or greater reduction in Psoriasis Area and Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical closure of Class II furcations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of residual defects to Class I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful withdrawal from bypass support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in VVA symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tumor necrosis factor-α (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: augmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: residual LM on staged excisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective comprehension score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in migraine days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability of intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: changes in visual functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative edema growth at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement based on mean CMS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-specific quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HI titers >or=1:32 after 2 doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of cross‐neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: methacholine dose shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean central subfield thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adherent bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine-associated risk
Endpoint domain: Adverse events/effects
Primary endpoint: biopsy-proven acute rejection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Anesthesia effect rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aBMD at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total and cortical volumetric bone mineral density (Tot. vBMD, Ct.vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone stiffness at the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Use of rescue salbutamol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to oral intake after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric dimensions for respirator design
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallow risk index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extreme step length changes after medial perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medial tibia cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermic effect of meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived ability to eat less
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Worsening of ophthalmopathy
Endpoint domain: Adverse events/effects
Primary endpoint: serum levels of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TAC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum MDA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum activity of T-SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum activity of GSH-Px
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morbidity-free neonatal survival
Endpoint domain: Mortality/survival
Primary endpoint: mean sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean interrater agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preparedness for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Mean concentration of plasma vitamin K1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of undercarboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin induced in vitamin K absence (PIVKA‐II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal plasma concentrations of cathinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to 9 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life of cathinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MoCA performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraarticular injection success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of stuttered syllables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Paresthesia during catheter insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Difficulty taking a deep breath and coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Moderate back pain after dissipation of chloroprocaine
Endpoint domain: Adverse events/effects
Primary endpoint: Stage III tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: maximum insulin concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: area under the plasma concentration time curve (AUC0‐24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximum glucose infusion rate (GIRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Variability in cigarettes smoked per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological reclassification rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDQ Total Difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: STSC score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of early ventilator-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose measurement exceeding thresholds
Endpoint domain: Adverse events/effects
Primary endpoint: Cr clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ΔFMD % values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of venous collaterals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of cold symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of illness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-100beta protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VADST performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of filarial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: gain in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraobserver variation (kappa coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver variation (intraclass correlation coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thermal thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: vibrotactile thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: finger systolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of Scr-based CIAKI
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodialysis independence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-operative pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DUI recidivism rates
Endpoint domain: Mortality/survival
Primary endpoint: Expression of immune receptors (CR1, FcgammaRI, FcalphaR, CR3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spontaneous stone expulsion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CV disease-related healthcare cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serious thromboembolic events
Endpoint domain: Mortality/survival
Primary endpoint: acute cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Cases of active TB
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial blush-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-segment resolution >or=50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: re-hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Objective alleviation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician response rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes